Literature DB >> 8283585

Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations.

R I Shorr1, R L Fought, W A Ray.   

Abstract

OBJECTIVES: To describe the changes in antipsychotic drug use in nursing homes during the period surrounding the implementation of federal legislation designed to reduce unnecessary use (the Omnibus Budget Reconciliation Act of 1987 [OBRA-87]) and to identify nursing home characteristics associated with such changes.
DESIGN: Longitudinal study of 9432 Tennessee Medicaid enrollees 65 years of age or older who continuously resided in Tennessee from April 1, 1989, to September 30, 1991, a 30-month period surrounding implementation of OBRA-87. MAIN OUTCOME MEASURES: Changes in the use of antipsychotic and other psychotropic drugs.
RESULTS: During the 30-month period, antipsychotic drug use decreased from 23.9 to 17.5 days per 100 days of residence, a 26.7% decline (P < .001), which resulted from both a decrease in new users (P < .001) and a reduction in long-term use of antipsychotic drugs (P < .001). There was no concomitant increase in other psychotropic drug use. A multivariate analysis revealed that changes in antipsychotic use were strongly associated with baseline antipsychotic use (P = .001) and third-shift staffing levels (P = .003). Nursing homes with baseline antipsychotic drug use and third-shift staffing above the median reduced antipsychotic drug use by 41%, compared with a 2% increase in nursing homes where both of these factors were below the median (P < .0001).
CONCLUSIONS: A substantial decrease in antipsychotic drug use coincided with the implementation of OBRA-87. Although this decrease is consistent with an improvement in quality of nursing home care, further research is needed to determine the effects of this legislation on resident outcomes.

Mesh:

Substances:

Year:  1994        PMID: 8283585

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  44 in total

1.  Impact of legislation on nursing home care in the United States: lessons for the United Kingdom.

Authors:  C M Hughes; K L Lapane; V Mor
Journal:  BMJ       Date:  1999-10-16

2.  Use of physical restraints and psychotropic medications in Alzheimer special care units in nursing homes.

Authors:  C D Phillips; K M Spry; P D Sloane; C Hawes
Journal:  Am J Public Health       Date:  2000-01       Impact factor: 9.308

Review 3.  The effectiveness of quality systems in nursing homes: a review.

Authors:  C Wagner; G van der Wal; P P Groenewegen; D H de Bakker
Journal:  Qual Health Care       Date:  2001-12

Review 4.  The drive for quality care in US nursing homes in the era of the prospective payment system.

Authors:  Carmel M Hughes; Kate L Lapane
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Factors influencing PRN medication use in nursing homes.

Authors:  Julie A Stokes; David M Purdie; Michael S Roberts
Journal:  Pharm World Sci       Date:  2004-06

Review 6.  Challenge of changing nursing home prescribing culture.

Authors:  Jennifer Tjia; Jerry H Gurwitz; Becky A Briesacher
Journal:  Am J Geriatr Pharmacother       Date:  2012-01-20

7.  Regulation and mindful resident care in nursing homes.

Authors:  Cathleen S Colón-Emeric; Donde Plowman; Donald Bailey; Kirsten Corazzini; Queen Utley-Smith; Natalie Ammarell; Mark Toles; Ruth Anderson
Journal:  Qual Health Res       Date:  2010-05-17

Review 8.  Administrative initiatives for reducing inappropriate prescribing of psychotropic drugs in nursing homes: how successful have they been?

Authors:  Carmel M Hughes; Kate L Lapane
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 9.  Psychotropic medication use for behavioral symptoms of dementia.

Authors:  Philip S Wang; M Alan Brookhart; Soko Setoguchi; Amanda R Patrick; Sebastian Schneeweiss
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

10.  Antipsychotic use among nursing home residents.

Authors:  Becky A Briesacher; Jennifer Tjia; Terry Field; Daniel Peterson; Jerry H Gurwitz
Journal:  JAMA       Date:  2013-02-06       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.